IPSEN (OTCMKTS:IPSEY) Shares Gap Down – Here’s Why

IPSEN (OTCMKTS:IPSEY) shares gapped down before the market opened on Thursday . The stock had previously closed at $46.2280, but opened at $44.82. IPSEN shares last traded at $44.82, with a volume of 125 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on IPSEY shares. HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Barclays cut IPSEN from an “equal weight” rating to an “underweight” rating in a research report on Tuesday, September 8th. Zacks Research upgraded IPSEN to a “hold” rating in a research note on Friday, May 29th. Finally, Jefferies Financial Group lowered IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

IPSEN Stock Performance

The firm has a 50-day simple moving average of $46.34 and a two-hundred day simple moving average of $46.70.

About IPSEN

Ipsen SA is a France-based biopharmaceutical company that develops and commercializes specialty medicines for serious diseases. Its primary focus areas are oncology, rare diseases and neuroscience, with research and development activities aimed at addressing conditions that often have limited treatment options.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and endocrine disorders, Dysport (abobotulinumtoxinA) for selected neurological and muscular conditions, and oncology treatments including Cabometyx and Onivyde.